|
MedChemExpress
erk5 proteolysis targeting chimera protac iny ![]() Erk5 Proteolysis Targeting Chimera Protac Iny, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/GW284543/pmc13085394-19-8-30 Average 93 stars, based on 1 article reviews
erk5 proteolysis targeting chimera protac iny - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
MedChemExpress
erk5 inhibitor jwg 071 ![]() Erk5 Inhibitor Jwg 071, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/JWG-071/pm41796389-64-0-3 Average 94 stars, based on 1 article reviews
erk5 inhibitor jwg 071 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
antibodies to erk5 ![]() Antibodies To Erk5, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/ERK5+Rabbit+mAb/pmc13049074-186-8-11 Average 94 stars, based on 1 article reviews
antibodies to erk5 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
erk5 ![]() Erk5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/Erk5+Antibody/us12551563-610-90-93 Average 96 stars, based on 1 article reviews
erk5 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
antibodies against erk5 ![]() Antibodies Against Erk5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/us12551563-604-24-27 Average 86 stars, based on 1 article reviews
antibodies against erk5 - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
anti erk5 antibody ![]() Anti Erk5 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/ERK+5+Antibody/pm41634806-127-7-9 Average 97 stars, based on 1 article reviews
anti erk5 antibody - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
rabbit anti phospho erk5 ![]() Rabbit Anti Phospho Erk5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/erk5/Phospho-Erk5+(Thr218%2FTyr220)+Antibody/pm41619450-63-29-32 Average 95 stars, based on 1 article reviews
rabbit anti phospho erk5 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
Journal: Cell Communication and Signaling : CCS
Article Title: MAPK ERK5 is a novel regulator of MHC-I in cancer cells
doi: 10.1186/s12964-026-02780-9
Figure Lengend Snippet: ERK5 inhibitor and PROTAC degrader enhance MHC-I membrane levels in 3D cultures of cancer cells and tumor xenografts. A , B 3D spheroid cultures of EC Ishikawa cells were treated for 24 h with either vehicle, 5 μM JWG-071 or 5 μM GW284543 ( A ), or with either vehicle, 300 nM PROTAC negative control INY-06–089 (Cont.), or 300 nM ERK5 PROTAC INY-06–061 ( B ). MHC-I surface expression was determined by FC analysis. A A representative image of untreated 3D cultures on day five is shown. Right histograms show the percentage of MHC-I expressing cells and MFI values. B Upper histograms show the percentage of MHC-I expressing cells and MFI values. Immunoblot shows ERK5 protein levels. A-B Data are the mean ± SD of a representative experiment from three independent experiments, each performed in triplicate. ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001, as determined by two-tailed Student’s t -test ( A ) or one-way ANOVA followed by Bonferroni multiple comparisons test ( B ). C Immunohistochemical analysis of the expression of surface MHC-I in tumors from nude mice engrafted with Ishikawa cells and treated either with vehicle or 50 mg/kg JWG-071 for 7 days. Scatter plot shows the percentage of cells expressing membrane MHC-I ( N = 5 mice per group, 5 fields per tumor; mean ± SD). Significance as determined by Mann–Whitney test
Article Snippet: ERK5 inhibitor JWG-071 (MedChemExpress), MEK5 inhibitor GW284543 (CliniSciences),
Techniques: Membrane, Negative Control, Expressing, Western Blot, Two Tailed Test, Immunohistochemical staining, MANN-WHITNEY
Journal: Cell Communication and Signaling : CCS
Article Title: MAPK ERK5 is a novel regulator of MHC-I in cancer cells
doi: 10.1186/s12964-026-02780-9
Figure Lengend Snippet: ERK5 does not regulate transcription of classical HLA-I genes or antigen-processing pathway. A , B ERK5/MEK5 inhibition does not alter mRNA levels of HLA-A , HLA-B , HLA-C , B2M , TAP1 and TAP2 genes. Ishikawa EC cells ( A ) or IMR-32 NBL cells ( B ) were treated for 24 h with either vehicle, or 5 μM JWG-071, or 5 μM GW284543 . Relative gene expression, normalized to TBP mRNA was assessed by RT-qPCR. KLF2 relative expression was used as a control for ERK5 or MEK5 inhibition. C , D Effect of ERK5 inhibition on the transcriptional programs of Ishikawa EC cells. Cells were treated for 24 h with 5 μM JWG-071, followed by RNA-seq analysis. Panels show gene set enrichment analysis (GSEA) for the Hallmark “Angiogenesis” and the GoBP “Cell migration” ( C ), and for the Reactome “Class I MHC mediated antigen processing presentation” pathway, the KEGG “antigen processing and presentation by MHC Class I” pathway, and the Biocarta “MHC Pathway” ( D ). E ERK5 inhibition does not enhance Golgi-to-plasma membrane transport of MHC-I. Ishikawa cells were treated for 24 h with either vehicle, or 5 μM JWG-071, or 250 nM brefeldin A (Bref.A), or the combination of both, and MHC-I surface expression was determined by FC. Histograms show MHC-I MFI values and the percentages of cells expressing MHC-I. F Effect of ERK5 inhibition and of the lysosome inhibitors chloroquine (CQ) and bafilomycin A (Baf.), on MHC-I levels. Ishikawa cells were treated for 24 h with either vehicle, or 5 μM JWG-071, or 10 µM chloroquine/150 nM bafilomycin (A), or the combination of both. Total MHC-I protein levels were determined by immunoblot analysis. Histograms show the quantification of MHC-I levels, referred to Hsp90. Autophagy marker LC3-I/II was used as a control for lysosome inhibitors, and Hsp90 as loading control. Data represent mean ± SD from three ( A , B , E ) or two ( F ) independent experiments. ns, not significant; ∗ p < 0.05; ∗∗ , $$ p < 0.005; ∗∗∗ p < 0.001; ∗∗∗∗ , $$$$ p < 0.0001, one-way ANOVA followed by Bonferroni multiple comparisons test
Article Snippet: ERK5 inhibitor JWG-071 (MedChemExpress), MEK5 inhibitor GW284543 (CliniSciences),
Techniques: Inhibition, Gene Expression, Quantitative RT-PCR, Expressing, Control, RNA Sequencing, Migration, Clinical Proteomics, Membrane, Western Blot, Marker
Journal: Cell Communication and Signaling : CCS
Article Title: MAPK ERK5 is a novel regulator of MHC-I in cancer cells
doi: 10.1186/s12964-026-02780-9
Figure Lengend Snippet: ERK5 inhibition enhances CD8 + T cell–mediated apoptosis of cancer cells. A Schematic representation of the protocol used to generate tumor-specific CD8 + T cells and their co-culture with human cancer cells. Tumor-specific antigens derived from IMR-32 or Ishikawa cancer cells were used to stimulate dendritic cells (DCs) derived from PBMCs of three healthy donors. Subsequently, T cells were activated and expanded. Finally, CD8 + T cells were isolated and co-cultured for 18 h with cancer cells pre-treated with either vehicle or JWG-071. The cytotoxic activity of CD8 + T cells in cancer cells was monitored by flow cytometry analysis of apoptosis (Annexin V/PI). B Representative dot plots of flow cytometry apoptosis assays for IMR-32 cells. C Bar graphs show the percentages of early (Annexin V +/PI-) and late (Annexin V +/PI +) apoptotic IMR-32 cells ( n = 3). Effector CD8 + T cells: target IMR-32 cells (E:T) ratios were 8:1 for donors 1 and 2, and 2:1 for donor 3. D Percentage of MHC-I + IMR-32 cells treated with either vehicle or JWG-071 and co-cultured with tumor-specific CD8 + T cells from three different donors. E Percentages of early and late apoptotic cells ( n = 3) for flow cytometry apoptosis assays performed with Ishikawa cells. Effector CD8 + T cells: target Ishikawa cells (E:T) ratios were 16:1, 8:1 and 12:1, respectively. F Percentage of MHC-I + Ishikawa cells treated with either vehicle or JWG-071 and co-cultured with tumor-specific CD8 + T cells from three different donors. Data represents mean ± SD from three independent experiments. ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.005, ∗ p < 0.05, determined by two-way ANOVA followed by Tukey multiple comparisons test
Article Snippet: ERK5 inhibitor JWG-071 (MedChemExpress), MEK5 inhibitor GW284543 (CliniSciences),
Techniques: Inhibition, Co-Culture Assay, Derivative Assay, Isolation, Cell Culture, Activity Assay, Flow Cytometry
Journal: Cell Communication and Signaling : CCS
Article Title: MAPK ERK5 is a novel regulator of MHC-I in cancer cells
doi: 10.1186/s12964-026-02780-9
Figure Lengend Snippet: ERK5 and MEK5 inhibitors enhance MHC-I surface expression in cancer cells without affecting PD-L1. A Effect of ERK5/MEK5 inhibitors in cancer cells with low basal MHC-I expression. IMR-32, Ishikawa and LNCaP cells were treated for 24 h with vehicle, 5 μM JWG-071 (ERK5i) or 5 μM GW284543 (MEK5i), and MHC-I surface expression was assessed by flow cytometry (FC). Left panels show representative FC histograms, and right panels show percentages of cells expressing MHC-I and the mean fluorescence intensity (MFI) values. B Effect of ERK5/MEK5 inhibitors in cancer cells with high basal MHC-I expression. ARK1, A549 and SW620 cells were treated as in ( A ), and MHC-I membrane expression was determined by FC. Representative FC histograms and MFI values are presented. C Effect of ERK5/MEK5 inhibitors in membrane PD-L1 expression in cancer cells with low basal MHC-I levels. IMR-32, Ishikawa and LNCaP cells were treated as in ( A ), or with 20 ng/mL IFN-γ or 8 µM MG-132 or 10 ng/mL TNF-α as positive controls. PD-L1 surface expression was measured by FC. Left panels show representative FC histograms, and right panels show percentages of cells expressing PD-L1 and MFI values. D Effect of ERK5/MEK5 inhibitors on total MHC-I protein levels. The indicated cells were treated with vehicle, 5 μM JWG-071 or 5 μM GW284543 for 24 h, and MHC-I protein levels were determined by immunoblot. The numbers indicate relative MHC-I protein levels referred to vehicle (mean ± SD from three independent experiments). Immunoblot ( D ) or qPCR analysis of p21 mRNA levels, as well as relative KLF2 gene expression ( E ) were used as controls for ERK5 inhibition. mRNA levels were normalized to TBP mRNA levels. F Effect of 5 μM ERK5i on MHC-I expression in Ishikawa ERK5 wild type (ERK5 +/+ ) and ERK5 CRISPR-KO (ERK5 −/− ) cells. Cells were treated 24 h and MHC-I membrane levels were assessed by FC (left panels show percentages of cells expressing MHC-I and MFI values), and total MHC-I protein levels by immunoblot (right panels). p21 levels were used as a control for ERK5 inhibition ( G ) Total MHC-I and ERK5 protein levels inversely correlate in cancer cells. Immunoblot analysis show MHC-I and ERK5 expression in the indicated cells. Right plot shows Pearson’s pairwise correlation analysis of relative levels of ERK5 and MHC-I protein expression in the cell lines tested. Data represents mean ± SD from three independent experiments. ns, not significant; ∗ p < 0.05; ∗∗ p < 0.005; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001, as determined by one-way ANOVA followed by Bonferroni multiple comparisons test
Article Snippet: ERK5 inhibitor JWG-071 (MedChemExpress), MEK5 inhibitor GW284543 (CliniSciences),
Techniques: Expressing, Flow Cytometry, Fluorescence, Membrane, Western Blot, Gene Expression, Inhibition, CRISPR, Control
Journal: Cell Communication and Signaling : CCS
Article Title: MAPK ERK5 is a novel regulator of MHC-I in cancer cells
doi: 10.1186/s12964-026-02780-9
Figure Lengend Snippet: ERK5 targeted degradation upregulates MHC-I membrane levels in cancer cells, whereas ERK5 overexpression reduces MHC-I expression. A - C ERK5 PROTAC degrader enhances MHC-I membrane levels in cancer cells with low basal MHC-I surface expression. IMR-32 ( A ), Ishikawa ( B ) and LNCaP ( C ) cells were treated for 24 h with vehicle, 300 nM PROTAC negative control INY-06–089, or 300 nM ERK5 PROTAC INY-06–061, and surface MHC-I (upper panels) and total MHC-I were determined by FC and immunoblot, respectively. GAPDH levels are shown as loading control. D ERK5 PROTAC degrader does not alter MHC-I in cancer cells with high basal MHC-I membrane levels. ARK1, A549 and SW620 cells were treated and analyzed as in ( A ). E ERK5 overexpression impairs MHC-I membrane expression in endometrial cancer cells. Ishikawa cells were co-transfected with vectors encoding for GST-tagged ERK5 and GFP, and MHC-I membrane expression was analyzed by FC within the GFP + cell population. Left bar graphs show the percentage of MHC-I expressing cells and the MFI values. Immunoblots show levels of ERK5 and MHC-I. p21 protein expression was used as control for ERK5 activity, and Hsp90 as loading control. The numbers indicate relative MHC-I protein levels (mean ± SD from three independent experiments). Results represent mean ± SD from three independent experiments. ns, not significant; ∗∗ p < 0.005; ∗∗∗∗ p < 0.0001 as determined by one-way ANOVA followed by Bonferroni multiple comparisons test ( A-D ) or two-tailed Student’s t -test ( E )
Article Snippet: ERK5 inhibitor JWG-071 (MedChemExpress), MEK5 inhibitor GW284543 (CliniSciences),
Techniques: Membrane, Over Expression, Expressing, Negative Control, Western Blot, Control, Transfection, Activity Assay, Two Tailed Test
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: High ERK5 mRNA expression inversely correlates with ferroptotic sensitivity. ( A ) ERK5 , ZEB1 and CDH2 mRNA expression in 860 cancer cell lines and correlation with their response to 481 compounds were curated from the CTRP portal. Z-scores represent standardised Pearson correlation coefficients between mRNA abundance (log₂ TPM from cancer cell line encyclopaedia RNA-seq) and the viability profiles of cancer cell lines in response to each drug across the DepMap dataset. Negative Z-scores indicate that high expression of ERK5, ZEB1 or CDH2 is associated with increased drug sensitivity, while positive Z-scores indicate relative resistance. Cut-off was set as 3 and − 3. ( B ) Cancer cell lines were ranked by ERK5 mRNA expression (log₂ TPM) and divided into the top 30% (ERK5-high) and bottom 30% (ERK5-low) cohorts. For each gene, gene effect scores downloaded from the DepMap portal, where lower values indicate greater dependency, were compared between groups. Gene effect difference was defined as the difference in median gene effect scores between ERK5-high and ERK5-low cell lines. Statistical significance was assessed using the Wilcoxon rank-sum test, and p-values were transformed to –log 10 for visualisation.
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Expressing, RNA Sequencing, Transformation Assay
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: XMD8-92 and JWG-045 exhibit an anti-ferroptotic activity. ( A ) RNA-sequencing datasets from DepMap were utilised to subdivide human cancer cell lines into epithelial-like and mesenchymal-like groups based on GSVA score established from epithelial and mesenchymal gene signatures. HER2-positive breast cancer BT474 and MDA-MB-453 cell lines were highlighted as epithelial-like cells, whilst triple negative breast cancer MDA-MB-231 and SUM159PT cells displayed a mesenchymal phenotype. ( B ) Levels of expression of ERK5 transcript in epithelial-like and mesenchymal-like human cancer cell lines (mean ± SD). *** p ≤ 0.001 (by unpaired t-test). ( C and D ) Quantification of cell density by crystal violet staining of BT474 and MDA-MB-231 cell lines treated with XMD8-92 (5 µM), JWG-045 (3 µM), Ferrostatin-1 (Fer-1, 1 µM) or RSL3 (250 nM), alone or in combination, for 24 h. Mock treated cells with DMSO were used as controls. The data are expressed as the mean percentage of cell density ± SD ( n = 4). One-way ANOVA was performed for statistical analyses.
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Activity Assay, RNA Sequencing, Expressing, Staining
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: Targeting ERK5 signalling by JWG-071, BAY-885 or BIX02189 does not protect breast cancer cells from ferroptotic death. BT474 (A, C and E) and MDA-MB-231 cells (B, D and F) were treated with XMD8-92 (5 µM), JWG-071 (3 µM), BAY-885 (5 µM), BIX02189 (5 µM), Ferrostatin-1 (Fer-1, 1 µM), or RSL3 (250 nM), as single agents or in combination, for 24 h unless indicated otherwise. Mock treated cells with DMSO were used as controls. ( A – D ) Cell density was quantified by crystal violet staining. The data are expressed as the mean percentage of cell density ± SD ( n = 3). ( E ) BT474 cells were monitored in the IncuCyte SX5 (Sartorius) using a phase-contrast camera, and cell confluency was quantified over a 20-hour period. Images were acquired every 2 h. The data are expressed as the mean fold of cell confluency ± SD ( n = 3). ( F ) Cell viability was quantified by CCK8 assay. The data are expressed as the mean percentage of cell viability ± SD ( n = 3). One-way ANOVA was performed for statistical analyses to compare the effect of RSL3 versus RSL3 combined with ERK5 inhibitor treatments.
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Staining, CCK-8 Assay
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: Effect of ERK5 inhibitors on RSL3-induced ferroptosis in ERK5 silenced MDA-MB-231 cells. ( A ) Immunoblot analysis of ERK5 expression in control (shScr) and ERK5 silenced MDA-MB-231 cells via stable expression of shERK5(UTR) and shERK5(CDS). β-tubulin expression was used as loading control. Similar results were obtained in two independent experiments. ( B – D ) Control and ERK5 silenced MDA-MB-231 cells were treated with XMD8-92 (5 µM), JWG-045 (3 µM), JWG-071 (3 µM), BAY-885 (5 µM), Ferrostatin-1 (Fer-1, 1 µM), or RSL3 (250 nM), as single agents or in combination, for 24 h. Mock treated cells with DMSO were used as controls. Cell density was quantified by crystal violet staining. One-way ANOVA was utilised to analyse statistical differences between mean percentages of cell density ± SD ( n = 3).
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Western Blot, Expressing, Control, Staining
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: XMD8-92 and JWG-045 suppress RSL3-induced ferroptosis in ERK5 knock-out SUM159PT cells. ( A ) Immunoblot analysis of ERK5 expression in parental (PT) and ERK5 KO SUM159PT cells. Where indicated, parental cells were mock treated with DMSO or treated with XMD8-92 (XMD8; 5 µM), JWG-045 (J-045; 3 µM), JWG-071 (J-071; 3 µM) or BAY-885 (B-885; 5 µM) for 1 h, followed by EGF (10 ng/mL) stimulation for 10 min. β-tubulin expression was used as loading control. Similar results were obtained in two independent experiments. The arrow indicates phosphorylated ERK5. ( B and C ) Parental and ERK5 KO SUM159PT cells were treated with XMD8-92 (5 µM), JWG-045 (3 µM), JWG-071 (3 µM), BAY-885 (5 µM), Ferrostatin-1 (Fer-1, 1 µM), or RSL3 (250 nM), as single agents or in combination, for 24 h. Mock treated cells with DMSO were used as controls. Cell density was quantified by crystal violet staining. One-way ANOVA was utilised to analyse statistical differences between mean percentages of cell density ± SD ( n = 3).
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Knock-Out, Western Blot, Expressing, Control, Staining
Journal: Scientific Reports
Article Title: XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
doi: 10.1038/s41598-026-42079-w
Figure Lengend Snippet: ERK5 is not required for mediating RSL3-induced ferroptosis in HeLa cells. ( A ) Immunoblot analysis of ERK5 expression in parental (PT) and ERK5 KO HeLa cells. Where indicated, parental cells were mock treated with DMSO or pre-treated with XMD8-92 (XMD8; 5 µM), JWG-045 (J-045; 3 µM), JWG-071 (J-071; 3 µM) or BAY-885 (B-885; 5 µM) for 1 h, followed by EGF (10 ng/mL) stimulation for 10 min. β-tubulin expression was used as loading control. Similar results were obtained in two independent experiments. The arrow indicates phosphorylated ERK5. ( B and C ) Parental and ERK5 KO HeLa cells were treated with XMD8-92 (5 µM), JWG-045 (3 µM), JWG-071 (3 µM), BAY-885 (5 µM), Ferrostatin-1 (Fer-1, 1 µM), or RSL3 (2500 nM), alone or in combination, for 24 h. Mock treated cells with DMSO were used as controls. Cell density was quantified by crystal violet staining. The data are expressed as the mean percentage of cell density ± SD ( n = 3). One-way ANOVA was performed for statistical analyses.
Article Snippet: The membranes were cut prior to hybridisation with
Techniques: Western Blot, Expressing, Control, Staining